Phase II trial of erlotinib and bevacizumab in patients with advanced upper gastrointestinal cancers

Author： Rohrberg Kristoffer S.   Olesen René K.   Pfeiffer Per   Ladekarl Morten   Pappot Helle   Christensen Ib J.   Høyer-Hansen Gunilla   Sørensen Morten   Skov Birgit G.   Buysschaert Ian   Carmeliet Peter   Lassen Ulrik  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.51, Iss.2, 2012-02, pp. : 234-242

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II Trial Evaluating Weekly Docetaxel and Capecitabine in Patients with Metastatic or Advanced, Locally Recurrent Head and Neck Cancers

By Zhang Jingsong   Lee Julia   Urba Susan   Foster Jared   Worden Francis  

Cancer Investigation, Vol. 28, Iss. 9, 2010-10 ,pp. : 910-916

Informa Healthcare

Access to resources Recommend Favorite

Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

By Motoshima Kohei   Nakamura Yoichi   Sano Kazumi   Ikegami Yoji   Ikeda Takaya   Mizoguchi Kosuke   Takemoto Shinnosuke   Fukuda Minoru   Nagashima Seiji   Iida Tetsuya   Tsukamoto Kazuhiro   Kohno Shigeru  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 6, 2013-12 ,pp. : 1299-1304

Springer Publishing Company

Access to resources Recommend Favorite

Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial

By Rossi David  

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 231-235

Springer Publishing Company

Access to resources Recommend Favorite

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

By            

Oncology Reports, Vol. 28, Iss. 3, 2012-01 ,pp. : 763-767

Spandidos Publications

Access to resources Recommend Favorite

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

By Wheler Jennifer   Janku Filip   Falchook Gerald   Jackson Tiffiny   Fu Siqing   Naing Aung   Tsimberidou Apostalia   Moulder Stacy   Hong David   Yang Hui   Piha-Paul Sarina   Atkins Johnique   Garcia-Manero Guillermo   Kurzrock Razelle  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 495-501

Springer Publishing Company

Access to resources Recommend Favorite